MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

Core Insights - MiNK Therapeutics, Inc. is set to release its Q3 2025 financial results on November 14, 2025, before market opening [1] - The company recently presented new clinical data for its agenT-797 iNKT cell therapy at the 2025 SITC Annual Meeting, showing durable immune reconstitution and activity in patients with advanced solid tumors [2] - A conference call and webcast will be held on the same day to discuss financial results, clinical progress, and upcoming milestones [2] Company Overview - MiNK Therapeutics is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators [4] - The lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure [5] - The company aims to deliver durable, accessible, and globally deployable immune reconstitution therapies through a scalable manufacturing process [5]